Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes

Sequel Med Tech obtained an FDA clearance opening up its twiist automated insulin delivery system to adults with type 2 diabetes.

Launched earlier this year for people with type 1 diabetes, the company estimates the agency’s green light adds about 5.5 million people in the U.S. who manage their condition with insulin.

Available through pharmacies with a prescription, the twiist carries a 300-unit insulin reservoir and is compatible with continuous glucose monitors including Abbott’s FreeStyle Libre 3 Plus and Senseonics’ Eversense 365.

Sign up for Blog Updates